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Abstract
MUC1 protein is an attractive target for anticancer drug delivery owing to its overexpression in most adenocarcinomas. In
this study, a reported MUC1 protein aptamer is exploited as the targeting agent of a nanoparticle-based drug delivery
system. Paclitaxel (PTX) loaded poly (lactic-co-glycolic-acid) (PLGA) nanoparticles were formulated by an emulsion/
evaporation method, and MUC1 aptamers (Apt) were conjugated to the particle surface through a DNA spacer. The aptamer
conjugated nanoparticles (Apt-NPs) are about 225.3 nm in size with a stable in vitro drug release profile. Using MCF-7 breast
cancer cell as a MUC1-overexpressing model, the MUC1 aptamer increased the uptake of nanoparticles into the target cells
as measured by flow cytometry. Moreover, the PTX loaded Apt-NPs enhanced in vitro drug delivery and cytotoxicity to
MUC1
+ cancer cells, as compared with non-targeted nanoparticles that lack the MUC1 aptamer (P,0.01). The behavior of
this novel aptamer-nanoparticle bioconjugates suggests that MUC1 aptamers may have application potential in targeted
drug delivery towards MUC1-overexpressing tumors.
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Introduction
Chemotherapy is a primary treatment for cancer, but its efficacy
is often limited due to associated adverse effects. Targeted drug
delivery system may overcome the non-specific toxicity of
chemotherapy because it may direct anticancer drugs to tumor
cells and avoid the toxicity to normal cells. In many cases,
nanoparticle (NP) has been proved of great potential for drug
delivery due to the passive tumor-targeting effect of enhanced
permeability and retention (EPR) exhibited by most nano-carriers
[1]. Moreover, an active targeting effect could be realized if a
targeting agent is conjugated to nanoparticle surface. In the past,
monoclonal antibodies (mABs) were the proposed targeting agents
[2]. Lately, novel targeting agents, including aptamers [3], short
peptides [4] and other small molecules [5], have become the new
generation targeting molecules. Aptamers are small strands of
DNA or RNA that could form unique 3-dimensional structures
that specifically combine to molecular targets with high affinity.
Comparing to other targeting agents, aptamers possess distinctive
advantages: low synthesis cost, low-immunogenicity, small size that
makes it easy to penetrate through solid tumors, and high affinity
comparable to monoclonal antibodies for binding to almost any
molecules. Previously, aptamers have been successfully applied as
targeting agents to enhance drug delivery to prostate cancer
[6,7,8] and lymphoblastic leukemia cells [9].
The above studies have paved the road for utilizing aptamer-
conjugated nanoparticle to develop targeted drug delivery systems.
However, most aptamer-guided nanoparticles studied so far aimed
at prostate cancer [6,7,8], and aptamer-guided nano-carriers for
drug delivery to other cancers have not been reported in literature.
It would be preferable if an aptamer targeting a broad spectrum of
cancers is employed to construct a targeted drug delivery system.
MUC1 mucin is a large transmembrane glycoprotein, whose
expression increased at least 10-fold in most malignant adenocar-
cinomas, making it an ideal target molecule for chemotherapeutics
[10]. The glycosylation and distribution of the protein at the cell
surface are abnormal in ovarian, lung, pancreatic and prostate
cancers, as well as in primary and metastatic breast cancers, which
is the most common cancer in women with 1.4 million cases
reported in 2008 [11]. Recently, several MUC1 aptamers were
developed by C.S.M. Ferreira et al. [12], and one of them was
applied to selectively deliver phototoxin to cancer cells in vitro [13].
So far, however, nanoparticle-based anticancer drug delivery
system targeting the MUC1 protein has not been reported in
literature. Among the published MUC1 aptamers, S2.2 is a 25-
base oligonucleotide that binds to MUC1 protein with relatively
high affinity and specificity [12,13]. In this study, we constructed a
MUC1 aptamer-conjugated nanoparticle with S2.2 for delivery of
paclitaxel to MUC1-positive tumor cells, combining the advan-
tages of aptamer as targeting agent and the strengths of
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evaluated its delivery efficacy in vitro using a MUC1-overexpressing
model MCF-7 cell line. We now report that the MUC1 aptamer-
nanoparticle enhances the delivery of anticancer drug to MUC1-
positive MCF-7 cells in vitro.
Materials and Methods
Materials
MUC1 aptamer S2.2 (59-GCA GTT GAT CCT TTG GAT
ACC CTG G-39) was synthesized by Invitrogen (Shanghai,
China). A modified aptamer S2.2-spacer, made of S2.2 and a
designed DNA spacer (59-GCA GTT GAT CCT TTG GAT
ACC CTG GTT CCC TTC CTT CTC TCT TCC TCT CTC
CTT CTC TCT TCC TCT CTC CTT C-39) was also
synthesized. Some aptamers were modified with 39-NH2 or 59-
FITC on an as needed base. Poly (lactic-co-glycolic-acid) (PLGA,
50:50, MW=16,000), N-hydroxysulfosuccinimide (NHS), 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC),
paclitaxel (PTX), 49,6-diamidino-2-phenylindole (DAPI), fluores-
cein isothiocyanate (FITC) and poloxamer 188 were all of
analytical grade.
MCF-7 and HepG2 cell lines were obtained from the Cell
Center of Chinese Academy of Medical Sciences (Beijing, China).
Cells were cultured in DMEM medium, supplemented with 100
units/ml aqueous penicillin G, 100 mg/mL streptomycin, and
10% FBS at concentrations to allow 70% confluence in 24 h.
Nanoparticle preparation
The paclitaxel encapsulated nanoparticles were prepared using
an emulsion/evaporation technique. Briefly, 0.1 mg PTX and
2.0 mg PLGA was dissolved in 0.2 ml ethyl acetate and mixed
with 1.0 ml 5% poloxamer aqueous solution for 30 s with
sonication (200 w) in an ice bath. The emulsion was gently stirred
and solvent evaporated at 40uC for 2 h. After evaporation, the
suspension was centrifuged at 100,000 g for 30 min. The
supernatant was removed and the precipitation was resuspended
in double-distilled water. For evaluation of the cellular uptake of
Apt-NPs, FITC was encapsulated into nanoparticles instead of
PTX, at the concentration of 0.25 mg/ml.
Characterization of nanoparticles
The particle size was determined by dynamic light scattering
(Malvern Zetasizer Nano ZS, UK). 1.0 mg NPs or Apt-NPs were
dissolved in 1.0 ml double-distilled water. The particle size
distributions were measured at a scattering angle of 90u. The
intensity-weighted mean value was recorded as the average of
three measurements.
To determine the PTX loading, 1.0 mg lyophilized PTX-Apt-
NPs were lysed in NaOH (1 M) and the UV absorbance
(Thermo Nanodrop 1000, US) was measured at a wavelength of
227 nm. 1.0 mg lyophilized plain NPs were used as parallel
controls to eliminate the impacts of the background. The PTX
was quantitatively determined by comparing to a standard
curve.
Conjugation of aptamers to nanoparticles
The conjugation of aptamers or random DNA to nanoparticles
was accomplished via crosslinking of –COOH and –NH2. Briefly,
50 ml of PTX-NPs (10 mg/ml in DNase RNase-free water) was
incubated with 100 ml of 40 mM 1-ethyl-3-(3-dimethylaminopro-
pyl) carbodiimide hydrochloride (EDC) and 100 mlo f1 0m MN-
hydroxysulfosuccinimide (NHS) for 15 minutes at room temper-
ature with gentle stirring. Then the activated particles were
covalently linked to 50 mlo f3 9-NH2–modified MUC1 aptamer
(1 mg/ml in DNase RNase-free water) or 39-NH2,5 9-FITC–
modified MUC1 aptamer on an as needed base, for 2 hours at
room temperature. The resulting aptamer-nanoparticle bioconju-
gates were washed, resuspended, and preserved in DNase RNase-
free water. The conjugation of 59-FITC, 39-NH2–modified MUC1
aptamer to PLGA microparticles (0.5 mg/ml) was analyzed by the
flow cytometry (Accuri C6, US).
Cellular binding of aptamers
The cellular binding of aptamers was determined by flow
cytometry (FCM) analysis of cells after incubation with FITC-
labeled random DNA (Ran), S2.2 aptamer, or S2.2-spacer. MCF-
7 and HepG2 cells were gently scraped and washed with D Hank’s
twice. The cells were suspended in the binding buffer (100 mM
NaCl, 5 mM MgCl2, pH 7.2) and incubated with Ran, MUC1
aptamer S2.2 or S2.2-spacer at the concentration of 300 nM for
30 min. The FCM analysis was performed to examine the binding
of random DNA or aptamers to both cell lines.
In vitro release profile of PTX from Apt-NPs
The in vitro release of PTX from Apt-NPs was detected by the
membrane diffusion technique. PTX-Apt-NPs were suspended in
phosphate buffer saline (PBS, pH 7.4) containing 0.5% (w/v)
poloxamer. 5 ml of the suspension (2 mg/ml) was introduced into
a dialysis bag (MWCO 3500) and then immersed into 95 ml
release medium in an incubator shaker set at 120 rpm at 37uC. At
the predetermined time intervals, samples were withdrawn and
replaced with fresh release medium. Nanoparticles and released
PTX were separated by ultra-centrifugation at 100,000 g for
30 min at 4uC. The PTX content in the supernatant was
determined by UV spectrophotometer at a wavelength of
227 nm. The cumulative release percentages of PTX from Apt-
NPs were calculated as follows and plotted against time.
Cumulative PTX released (%)~
amount of released PTX
amount of total PTX in Apt-NPs
|100%
Cellular uptake experiment
The cellular uptake of the particles was determined by FCM
analysis of cells after incubation with FITC encapsulated particles.
MCF-7 and HepG2 cells were grown in 24-well plates for 24 h.
The cells were then incubated with 50 mg/ml FITC encapsulated
NPs or Apt-NPs for 2 h at 37uC. The FCM analysis was then
performed to examine the cellular fluorescence uptake of both
cancer cell lines.
Confocal fluorescence scanning microscopy
The cellular uptake of NPs or Apt-NPs by MCF-7 was further
studied by confocal fluorescence scanning microscopy (Perkin
Elmer Ultraview, US). MCF-7 cells were allowed to adhere to a
glass cover slip in 6-well plate for 24 h. The cells were then
incubated with 100 mg/ml NPs or Apt-NPs, both containing
FITC, for 2 h at 37uC. Then the cells were washed with D
Hank’s and treated with 0.25% trypsin for 1 min. The
suspended cells were transferred to a centrifuge tube and
washed twice. The cells were then fixed with 4% formaldehyde
for 10 min at 4uC and analyzed by confocal fluorescence
scanning microscopy.
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To evaluate the cytotoxicity effects of PTX-Apt-NPs against
MCF-7 and HepG2 cells, both cell lines were grown in 96-well
plates. The cells were treated with plain NPs, free PTX, PTX-
loaded NPs (PTX-NPs) and PTX-loaded Apt-NPs (PTX-Apt-
NPs). PTX-loaded NPs conjugated to random DNA (PTX-R-NPs)
was also used to serve as another control. MCF-7 and HepG2 cells
were co-cultured with the respective substances at an equivalent
PTX dose of 0.05 mg/ml for 4 h at 37uC, then washed with D
Hank’s (26500 ml per well). Cells were cultured for a further 48 h
and then MTS assay (Promega, US) was used to determine the cell
viability per standard protocol outlined by the manufacture.
Statistical analysis
Statistical analysis was performed using Statistical Analysis
System (SAS, Version 9.2). One-way ANOVA with Fisher’s least
significant difference (LSD) post hoc comparisons at 99%
confidence interval was used for statistical comparisons. All data
are presented as a mean value with its standard deviation indicated
(mean 6 SD).
Results
Preparation of Apt-NPs
PTX-Apt-NPs were constructed as outlined in Fig. 1 using a
routine emulsion/evaporation method. PTX was incorporated
into NPs by physical entrapment through hydrophobic interac-
tions between PTX and PLGA (Fig. 1B). In order to facilitate
polyvalent binding between the aptamer and the target, a spacer is
often inserted between the aptamer and the nanoparticle vehicle.
Hence we constructed a DNA spacer by extending the 39 end of
the original S2.2 aptamer with 48 additional bases (Fig. 1A),
providing a spacer length close to that of PEG 3400, which is a
commonly used spacer in targeted drug delivery systems [14,15].
The extended portion of DNA will not affect the secondary
structure of the S2.2 aptamer per computational analysis
(RNAstructure, version 4.5). To conjugate the aptamer-spacer
complex to PTX-loaded NPs, EDC and NHS were added to
catalyze the formation of covalent couple between the -COOH of
PLGA on the nanoparticle surface and the 39-NH2 MUC1
aptamer (Fig. 1B). The drug loaded nanoparticle size is
164.067.6 nm before coupling to aptamers, and increased to
225.369.2 nm after the conjugation, presumably because of the
added size of the aptamer and spacer. The PTX encapsulation
efficacy was 83.661.7% with a drug load of 4.260.1%.
Affinity of MUC1 aptamer to MCF-7 and HepG2 cell lines
The aptamer S2.2 is reported to specifically bind to MUC1
protein with high affinity [12]. To test whether S2.2 would
differentially bind to MUC1-positive and MUC1-negative cells, the
binding of S2.2 to MCF-7 and HepG2 cells was evaluated by FCM
analysis. A random DNA (Ran) was used as control. Previous study
have well established that MCF-7 is a human breast cancer cell line
that overexpresses MUC1 protein on its surface [16], and that
HepG2 is a MUC1-negative human hepatic cancer cell line [17].
Consistent with the original report, the aptamer S2.2 (yellow curve)
demonstrated a higher binding to the MUC1-positive MCF-7 cells
than the MUC1-negative HepG2 cells (Fig. 2 A&B). The random
DNA (blue curve) had a much lower binding to both MCF-7 and
HepG2 cells, presumably resulted from non-specific binding.
Furthermore, to examine if S2.2-spacer had a similar binding
preference for the MUC1-positive cells, the binding experiment was
repeated for S2.2-spacer. The results exhibited that the S2.2-spacer
(red curve) had similar interaction with both cells as S2.2 (Fig. 2
Figure 1. Construction of the S2.2-spacer aptamer and PTX-Apt-NPs. (A) Structure of MUC1 aptamer S2.2-spacer. The S2.2-spacer is made of
the MUC1 aptamer S2.2 (as the targeting agent) and a designed sequence of single strand DNA (as the linking spacer). (B) Preparation procedure for
PTX-Apt-NP using the emulsion/evaporation method.
doi:10.1371/journal.pone.0024077.g001
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ability of the original aptamer. The mean fluorescent intensity of
FITC-labeled S2.2-spacer binding with MCF-7 is 3.5 times higher
than that with HepG2, making it a qualified targeting agent for
selectively aiming at the MCF-7 cells. Since a spacer may facilitate
polyvalent binding between the aptamer and the target, S2.2-spacer
was applied as the targeting agent to construct the drug delivery
system in this study.
Evaluation of conjugation between aptamers and
nanoparticles
The MUC1 aptamer-spacer was conjugated to nanoparticle in
the reaction catalyzed by EDC and NHS. To ensure that the DNA
aptamer was indeed linked to the surface of the particle, two
experiments were conducted. In the first experiment, FITC-
labeled aptamer was co-incubated with microparticles (MPs) either
in the presence or in the absence of the catalysts EDC and NHS,
and then analyzed by the FCM. As shown in Fig. 3A, the particle
fluorescent intensity in the absence of EDC and NHS was nearly
identical to that of the plain MPs, while a positive fluorescence was
observed in the presence of EDC and NHS. The results suggested
the conjugation between aptamers and particles was indispensably
enabled by the catalysts, and that aptamers were stably conjugated
to the particles through covalent linkage. The second experiment
examined the presence of DNA aptamer on nanoparticles by UV
spectroscopy and evaluated the conjugating efficacy. Similar to the
FCM results, more aptamers were linked to nanoparticles in the
presence of EDC and NHS (Fig. 3B). The amount of conjugated
aptamers on NPs was also estimated. In this reaction system,
approximately 0.1 nmol aptamers were covalently coupled to
1 mg PLGA NPs, or about 120 aptamers for each nanoparticle.
In vitro release profile of PTX from Apt-NPs
We next studied the in vitro release profile of the PTX from the
Apt-NPs, a necessary property for anticancer activity. The amount
of PTX release in PBS was assayed overtime with UV absorption
at 227 nm. A typical kinetics of sustained release process was
observed for PTX, with about 65% of the drug gradually released
over the first 48 hours (Fig. 4). The proportion of PTX released
here was in line with the releasing profiles of many PLGA drug
carrier systems reported in literature [18,19,20].
Cellular uptake experiment
The most important property of a targeted drug delivery system
is its specificity towards the target cells. To explore the in vitro
cancer targeting of the Apt-NPs against the MUC1-overexpressing
cells, we compared the cellular uptake of MCF-7 (MUC1
+) and
HepG2 (MUC1
2) using FCM analysis (Fig. 5). NPs and Apt-NPs,
Figure 2. FCM analysis of MCF-7 and HepG2 cells incubated with random DNA, MUC1 aptamer S2.2, or S2.2-spacer. (A) Histograms of
FCM analysis. FITC-labeled random DNA, S2.2, or S2.2-spacer was incubated separately with MCF-7 (left) and HepG2 (right) cells. (B) The mean
fluorescent intensity of MCF-7 and HepG2 cells incubated with random DNA and different aptamers.
doi:10.1371/journal.pone.0024077.g002
Aptamer-Nanoparticle Enhances Paclitaxel Delivery
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24077both encapsulating FITC, were co-cultured with MCF-7 and
HepG2. Fluorescent intensity of MCF-7 and HepG2 cells
incubated with NPs were similar in amplitude. However, for
Apt-NPs treated MCF-7 cells, the fluorescent intensity increased
by 71%, while that of HepG2 cells hardly changed. The
distinction was presumably caused by the conjugated aptamers,
which bound to the MUC1 protein on the surface of MCF-7 cells,
resulting in more nanoparticles being attached to the cell surface
and internalized into the cell.
Confocal fluorescent scanning microscopy
The above results showed that Apt-NPs generated enhanced
fluorescence intensity in MUC1-positive MCF-7 cells, comparing
with NPs. However, it was not entirely clear whether the Apt-NPs
were attached to the cell surface or internalized into the cells. To
further study the interaction scheme between Apt-NPs and the
target cells, confocal fluorescent scanning microscopy was
performed to determine the location of Apt-NPs. Multiple images
scanning through various levels of the MCF-7 cells were obtained.
The central level scans that went through the center of the cell and
the nuclei were displayed in Fig. 6. The images clearly indicated
that the Apt-NPs were mainly accumulated in the cytoplasm
around the nucleus. Accordingly, Apt-NPs could be internalized
into the target cells and carry the anticancer drugs into the
cytoplasm. Compared to Apt-NPs, the amount of NPs entered
MCF-7 cells was much less; suggesting again that the MUC1
aptamer facilitated the uptake of nanoparticles into the cells.
In vitro cytotoxicity
The cellular uptake experiment showed that Apt-NPs increased
the uptake of nanoparticles by MUC1-overexpressing tumor cells.
However, it is unknown how this will affect the delivery of
anticancer agent to the cells. To study the issue, in vitro cytotoxicity
of free PTX, plain NPs, PTX-loaded NPs (PTX-NPs), PTX-
loaded NPs conjugated to random DNA (PTX-R-NPs), and PTX-
loaded NPs conjugated to MUC1 aptamers (PTX-Apt-NPs) were
compared using MCF-7 (MUC1+) and HepG2 (MUC1-) as target
cells. The results are presented in Fig. 7. Plain NPs showed little
cytotoxicity, suggesting that the delivery vehicles are relatively
nontoxic to the cells and that the cytotoxicity was mostly caused by
the encapsulated PTX. Free PTX generated similar degrees of
cytotoxicity in both cell lines. PTX-Apt-NPs produced a more
potent cytotoxicity than PTX-NPs or PTX-R-NPs in MCF-7 cells
(P,0.01). However, the cytotoxicity differences were not observed
in HepG2 cells. This is consistent with the results shown in Fig. 5,
in which MUC1 aptamer increased the uptake of Apt-NPs into
MCF-7 cells (MUC1+) but not HepG2 cells (MUC1-). The results
suggest that the MUC1 aptamer may selectively enhance the
delivery of anticancer drug to MUC1-positive cancer cells.
Discussion
Targeted drug delivery systems have been proposed to solve the
problem that most anticancer therapeutic agents fail to act
specifically on cancer cells and cause toxicity to normal cells. In
this study, we designed a MUC1 aptamer-based targeted drug
Figure 3. Analysis of aptamer conjugation to microparticles or nanoparticles. The PLGA microparticles (MPs) or nanoparticles (NPs) reacted
with aptamers in the absence (-EDC&NHS) or presence (+EDC&NHS) of the catalysts. (A) Histograms of FCM analysis of MP reacted with FITC-labeled
aptamers in the absence (-EDC&NHS, left) or presence (+EDC&NHS, right) of the catalysts. Plain microparticles that had not reacted with aptamers
were used as control. (B) UV absorption of DNA at 260 nm (n=3) on the particles that underwent conjugation process with aptamers. The control
group (NPs) indicates plain nanoparticles that have not reacted with DNA aptamers.
doi:10.1371/journal.pone.0024077.g003
Figure 4. In vitro drug release profile of the PTX encapsulated
Apt-NPs. The experiment was conducted in phosphate buffer saline
(PBS, pH 7.4) containing 0.5% (w/v) poloxamer using the membrane
diffusion technique, (n=3).
doi:10.1371/journal.pone.0024077.g004
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MUC1-overexpressing tumor cells. The MUC1 aptamers dem-
onstrated higher affinity and selectivity against MCF-7 cells
(MUC1
+) over HepG2 cells (MUC1
2) (Fig. 2). To construct the
Apt-NPs, MUC1 aptamers were conjugated the aptamers to NPs
surface through chemical covalent coupling (Fig. 3). The Apt-NPs
showed a profile of sustained drug release (Fig. 4). The targeting
aptamer increased the uptake of nanoparticles into MUC1-
overexpressing tumor cells (Fig. 5 & 6). Moreover, the Apt-NPs
enhanced the PTX delivery to the MUC1-positive tumor cells
(Fig. 7) while showing no efficacy towards the control cells.
Previous studies of aptamer-conjugated NPs for drug delivery
have improved efficacy against prostate cancer via an aptamer of
prostate-specific membrane antigen (PSMA) [6,7,8,21]. However,
it would be ideal to construct an aptamer-based drug delivery
system targeting a broad spectrum of cancers. MUC1 protein is
overexpressed and aberrantly glycosylated on the surface of most
adenocarcinoma cells [10], making it a very attractive target for
cancer therapy. In this study, for the first time, MUC1 aptamer is
exploited as a targeting agent in a nanoparticle-based drug
delivery system. The MUC1 aptamer (S2.2) used in this study
exhibited high binding affinity to MUC1, which is comparable to
the anti-MUC1 antibody C595 [12,22]. The targeted nanoparticle
delivery system based on this MUC1 aptamer was evaluated for its
targeting capability against the MCF-7 cells in vitro. Similar to the
drug delivery system based on PSMA aptamer, we observed
enhanced uptake of Apt-NPs by MUC1-overexpressing MCF-7
cells (Fig. 7). Since MUC1 protein is overexpressed on the surface
of multiple types of cancer cells, such a drug delivery system may
potentially improve the delivery of anticancer agents to multiple
malignancies, such as pancreatic cancer [23], prostate cancer [24],
ovarian cancer [25], etc.
Figure 5. FCM analysis of cellular uptake of Apt-NPs and NPs by MCF-7 (left) and HepG2 cells (right). The cells were incubated with FITC
encapsulated Apt-NPs or NPs at 50 mg/ml for 2 hours before subject to analysis.
doi:10.1371/journal.pone.0024077.g005
Figure 6. Confocal fluorescent scanning microscopy images detecting cellular uptake of Apt-NPs (top row) or NPs (bottom row) in
MCF-7 cells. Green fluorescent FITC was encapsulated in Apt-NPs and NPs. The nuclei were stained blue with DAPI. The right column showed the
merged images of the FITC and the DAPI channels. MCF-7 cells were exposed to FITC-encapsulated Apt-NPs or NPs at 100 mg/ml for 2 hours.
doi:10.1371/journal.pone.0024077.g006
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was mainly induced by the MUC1 aptamer. The confocal
scanning microscopy images (Fig. 6) and the increased cytotoxicity
comparing to free PTX (Fig. 7) indicated that the NPs were
internalized into the cells. Generally it is thought that drug-loaded
PLGA NPs are taken up by cells through internalization, and
subsequently release the drug inside the cells [26]. The S2.2
aptamers conjugated to the NPs probably promoted the
interaction between NPs and MCF-7 cells via ligand-receptor
recognition. Specifically, the S2.2 bound to MUC1 presumably
acted like an anchor and pulled the nanoparticle to the vicinity of
the cell, and improved the chances of the nanoparticle being
internalized by MCF-7 cells. For MUC1-negative HepG2 cells,
the aptamer failed to enhance the uptake of nanoparticle (Fig. 5),
presumably because it did not improve the interaction between the
nanoparticle and the cell.
A spacer molecule is often needed between the targeting
molecule and the carrier nanoparticle: the length and flexibility of
the spacer allows the targeting aptamers penetrate through the cell
surface molecules and bind to the targets in a polyvalent way [14].
In this study, we attempted a novel approach to construct a spacer,
which could simplify the preparation procedure. We extended the
25-base S2.2 aptamer by adding a 48-base DNA sequence to the
39 end of the aptamer, to make a 73-base strand. The DNA spacer
was designed to avoid forming secondary structure and had
approximately the same length as the mostly used spacer PEG-
3400 (25 nm). The binding experiment (Fig. 2) proved that
aptamer S2.2 and S2.2-spacer had similar binding profiles with the
MUC1-positive target cells and MUC1-negative control cells.
These results suggested that the extended DNA strand did not
affect the binding capability of S2.2 and could serve as a feasible
spacer. By avoiding the PEG spacer, this construction method
simplified the chemistry of conjugating targeting agent and spacer
to nanoparticle. Since the advantages of the spacer has been well
approved [27,28] and the S2.2-spacer demonstrated good affinity
to MUC1-positive target cells, aptamers with DNA spacer were
utilized to construct the targeted drug delivery system in this
research. As expected, the S2.2-spacer conjugated Apt-NPs
displayed high specificity and affinity towards MUC1-overex-
pressing cells in vitro.
MUC1 protein is an important tumor-associated antigen (TAA)
detected in most adenocarcinomas. Recently, a group of MUC1
aptamers have been identified, including the aptamer S2.2 [12],
which has the potential to serve as targeting agent for MUC1
protein. The primary goal of this study is to explore the possibility
of developing a nanoscale drug delivery system based on S2.2 and
to preliminarily evaluate its cancer-targeting capability in vitro.
Here we constructed a novel PTX-loaded nanoparticle conjugated
to MUC1 aptamer S2.2 through a DNA spacer. The aptamer was
found to increase the uptake of nanoparticles into MUC1-positive
MCF-7 cells. Moreover, the PTX-loaded Apt-NPs enhanced the
cytotoxicity against MCF-7 cells in vitro. Nevertheless, in order to
practically realize MUC1-targeted drug delivery, extensive future
research on the Apt-NPs is still warranted, including detailed in vivo
evaluation of pharmacokinetics, pharmacodynamics, adverse
effects and long-term biocompatibility in animal studies.
Conclusion
In summary, a MUC1 aptamer-guided nanoscale drug delivery
system was developed with a novel conjugation strategy. The
results demonstrate that the system can effectively enhance the
PTX delivery to MUC1- overexpressing MCF-7 cells in vitro. Since
many cancers overexpress MUC1 protein, we postulate that
targeted drug delivery aiming at MUC1 may serve as a potential
strategy to improve the treatment outcome of these tumors.
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